Home
About
Pricing
Log In

What are you looking for?

Home
Pricing
Back
Compare AU

Compare CURE vs. IPAY

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

---

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and IPAY. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

CURE

---

Popularity

Low

N/A

Pearlers invested

69

0

Median incremental investment

$665.63

-

Median investment frequency

Monthly

N/A

Median total investment

$1,888.96

$0

Average age group

> 35

N/A

Key Summary

CURE

---

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

N/A

Top 3 holdings

Moderna Inc (1.72 %)

Roivant Sciences Ltd Ordinary Shares (1.65 %)

Mirum Pharmaceuticals Inc (1.60 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (96.62 %)

United Kingdom of Great Britain and Northern Ireland (1.35 %)

Switzerland (1.13 %)

Management fee

0.45 %

N/A

Key Summary

CURE

---

Issuer

Global X

N/A

Tracking index

S&P Biotechnology Select Industry

N/A

Asset class

ETF

Stock

Management fee

0.45 %

N/A

Price

$59.03

$--

Size

$39.710 million

N/A

10Y return

N/A

N/A

Annual distribution/ dividend yield (5Y)

5.08 %

- %

Market

ASX

ASX

First listed date

12/11/2018

N/A

Purchase fee

$6.50

$6.50

Community Stats

CURE

---

Popularity

Low

N/A

Pearlers invested

69

0

Median incremental investment

$665.63

-

Median investment frequency

Monthly

N/A

Median total investment

$1,888.96

$0

Average age group

> 35

N/A

Pros and Cons

CURE

---

Pros

  • Exposure to more markets and sectors

  • Higher dividend/distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Exposure to 1 market and 1 sector only

  • Lower dividend/distribution yield

CURE

---

Exposure to more markets and sectors

Exposure to 1 market and 1 sector only

Lower price growth

Higher price growth

Higher dividend/distribution yield

Lower dividend/distribution yield